Open AccessHow to sequence treatment in relapsed ovarian cancer
Author(s) -
Sandro Pignata,
Sabrina Chiara Cecere
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1122
Subject(s) - medicine , trabectedin , olaparib , oncology , ovarian cancer , disease , bevacizumab , chemotherapy , carboplatin , topotecan , regorafenib , cancer , surgery , poly adp ribose polymerase , polymerase , cisplatin , biochemistry , soft tissue , chemistry , soft tissue sarcoma , gene , colorectal cancer
Numerous disease- and patient-related factors must be considered when selecting systemic therapy for recurrent ovarian cancer. Anti-angiogenics (bevacizumab) and poly(ADP-ribose) polymerase inhibitors (olaparib, niraparib and rucaparib) have an important role as maintenance of platinum-based chemotherapy for recurrent disease and their use in the first-line setting of advanced-stage disease is becoming established. As previous exposure to none, one or both of these drug classes is integral to selecting next therapy, front-line use impacts on options available to treat recurrent disease. A key strategy to delay platinum resistance and improve prognosis of recurrent disease is to alternate treatments with different mechanisms of action. The multiple mechanisms of trabectedin and its complementarity with platinum allow intercalation between platinum regimens in potentially platinum-responsive patients with recurrent disease.